Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Epilepsy 2Tuberous Sclerosis Complex-associated Refractory Seizures 1Tuberous Sclerosis 1Seizures 1Gliosarcoma 1Glioma 1Glioblastoma 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chronic Pain 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Levetiracetam 6Cannabidiol 4perampanel 2Standard of Care 2Everolimus 2enzalutamide 1Vigabatrin 1Tranexamic Acid 1Temozolomide 1Sodium Chloride 1Saline Solution 1Pregabalin 1Medical Marijuana 1Magnesium Sulfate 1Drug Therapy 1Curcumin 1Cholecalciferol 1Aspirin 1Anticonvulsants 1Anastrozole 1Airway Extubation 12-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Seizures × Anticonvulsants × Clear all
NCT03356769 2020-06-09

Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

Peking Union Medical College Hospital

Phase 2 Unknown
98 enrolled

Epilepsy, Seizures, Tuberous Sclerosis, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡